Natera (NTRA), CytoDyn Announce Strategic Collaboration for ctDNA-Guided mCRC Clinical Trials
Natera Inc. (NASDAQ:NTRA) is one of the 12 Best Growth Stocks Trading in Oversold Territory. On June 4, Natera and CytoDyn entered a strategic collaboration to utilize ctDNA-guided insights and molecular response analysis for CytoDyn’s metastatic colorectal cancer (mCRC) development program. Under the agreement, Natera will use its Signatera personalized MRD assay to evaluate clinical trial samples from CytoDyn’s CLOVER Phase 2 study, focusing on ctDNA dynamics and response patterns linked to the monoclonal antibody leronlimab.
The partnership also grants CytoDyn access to Natera Inc.’s (NASDAQ:NTRA) proprietary oncology database, which integrates molecular response data with curated electronic medical records. By leveraging this large-scale multimodal dataset, the companies aim to analyze treatment patterns and disease progression to better inform future clinical trial designs, biomarker-driven patient selection, and overall development strategies for leronlimab.
This collaboration follows the completion of enrollment for the CLOVER study, which is investigating leronlimab in combination with standard therapies for previously treated mCRC patients. Both companies anticipate that these combined molecular and real-world insights will provide a deeper understanding of treatment response, potentially supporting the future expansion of leronlimab into additional solid tumor indications.
Natera Inc. (NASDAQ:NTRA) is a global leader in cell-free DNA and precision medicine, providing highly certified, personalized genetic diagnostics for oncology, women’s health, and organ health.
While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.